Scientists investigate the ‘type 3 diabetes’ concept, highlighting insulin’s role in brain health and cognitive decline, yet caution that the theory remains unproven as a clinical diagnosis. For more than two decades, some researchers have used the term “type 3…
As Medicare standardises remote patient monitoring for chronic care, commercial insurers take a more cautious, condition-specific approach, with policy changes and billing nuances set to reshape care delivery from late 2025 onwards. Remote patient monitoring has moved into a more…
As Tenovi promotes its connected Trividia Blood Glucose Meter for remote patient monitoring, recent FDA safety alerts and recalls cast doubt on device reliability, underscoring the complexities of home diabetes care. Tenovi’s guide to the Trividia Blood Glucose Meter presents…
Eli Lilly reports stronger-than-expected outcomes from its experimental combination therapy EloraTZP, potentially expanding its dominance in cardiometabolic medicine and accelerating its path to late-stage trials. Eli Lilly said on Tuesday that a mid-stage trial of its experimental obesity and diabetes…
A comprehensive review presented at the European Association for the Study of Diabetes indicates that GLP-1 drugs do not significantly increase adverse pregnancy outcomes, though calls for more definitive evidence persist. New research to be presented at the European Association…
As Milan hosts the 62nd European Association for the Study of Diabetes, Eli Lilly uses public initiatives, including a restored tram and pop-up installations, to make cardiometabolic health more accessible and connect medical advances with everyday life. As Milan prepares…
Preliminary findings from a large French cohort suggest that a naturally occurring sugar in red meat may contribute to higher diabetes risk, highlighting the importance of food composition beyond consumption levels. A compound found naturally in red meat may be…
Novo Nordisk has agreed to licence HRS-1596, an innovative phase I-ready oral dual agonist for obesity and diabetes from Hengrui Pharma, signalling a push to expand oral metabolic therapies amidst fierce industry competition. Novo Nordisk has agreed to license HRS-1596,…
A new study indicates that for older US veterans with long-standing diabetes, adding GLP-1 receptor agonists does not significantly reduce the need for insulin, highlighting the importance of comprehensive treatment plans. For many people with type 2 diabetes, GLP-1 medicines…
Emerging field of metabolic psychiatry suggests that targeting metabolic dysfunction through diet and medications could transform treatment for mental health disorders, shifting focus from managing symptoms to addressing biological drivers. Metabolic psychiatry is emerging as a way of rethinking some…
